Product image of Lacosamide Ucb (Lacosamide) supplied by GNH India

Lacosamide Ucb

Active Ingredient:
Lacosamide
Origin:
EU

Lacosamide Ucb (Lacosamide)

Lacosamide, the active ingredient in Lacosamide Ucb, is a sodium channel blocker presented as an injection for intravenous use. It is indicated as adjunctive therapy for partial‑onset seizures in patients with epilepsy. The formulation is intended for use in acute care settings where rapid plasma concentrations are required.

GNH India supplies Lacosamide Ucb as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures timely delivery and compliance with local regulatory requirements.

Manufacturer / TM Owner

Ucb Pharma S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Lacosamide is an antiepileptic drug used as adjunctive therapy for focal seizures.
  • Partial‑onset seizures (adults): adjunctive therapy to reduce seizure frequency.
  • Partial‑onset seizures (children ≥4 years): adjunctive therapy to reduce seizure frequency.
  • Focal seizures with secondary generalisation: adjunctive therapy to improve seizure control.

How It Works

  • Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilising hyperexcitable neuronal membranes. By selectively prolonging the inactivated state of these channels, it reduces repetitive neuronal firing without affecting normal physiological activity, thereby decreasing the propagation of epileptic discharges.

Side Effects

Lacosamide may be associated with a range of adverse reactions, varying in frequency and severity.

Common Side Effects

  • Dizziness: sensation of light‑headedness or unsteadiness.
  • Nausea: mild to moderate upset stomach.
  • Fatigue: feeling unusually tired or weak.
  • Headache: mild to moderate cranial pain.
  • Diplopia: transient double vision.

Serious or Rare Side Effects

  • Cardiac conduction abnormalities: PR‑interval prolongation or arrhythmia.
  • Suicidal ideation: thoughts of self‑harm requiring immediate evaluation.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Respiratory depression: reduced breathing effort, especially with CNS depressants.
  • Anaphylaxis: acute allergic reaction with airway compromise.

Precautions & Warnings

  • When prescribing Lacosamide, clinicians should consider several safety factors.
  • Renal impairment: dose may require adjustment based on renal function.
  • Hepatic impairment: monitor liver enzymes and consider dose modification.
  • Cardiac conduction: obtain baseline ECG and monitor for PR‑interval changes.
  • Pregnancy: use only if potential benefit justifies potential risk to the fetus.
  • Drug‑specific warnings: avoid abrupt discontinuation to reduce seizure recurrence risk.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Lacosamide can interact with several medication classes, requiring careful management.

Major Interactions (Avoid)

  • Other sodium channel blockers (e.g., carbamazepine, phenytoin): increased risk of CNS depression.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may raise lacosamide plasma levels.
  • Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower lacosamide exposure.
  • Opioids (e.g., morphine, fentanyl): heightened risk of respiratory depression.
  • Alcohol: additive CNS depressive effects.

Moderate Interactions (Monitor Closely)

  • Anticoagulants (e.g., warfarin): may require INR monitoring.
  • Antidepressants (e.g., SSRIs, SNRIs): may increase dizziness or somnolence.

Frequently Asked Questions

Lacosamide Ucb is an intravenous formulation of the antiepileptic agent lacosamide. It is approved as adjunctive therapy for partial‑onset (focal) seizures in patients with epilepsy, helping to reduce seizure frequency when added to existing antiseizure regimens.

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilises hyperexcitable neurons, limits repetitive firing, and thereby diminishes the spread of epileptic activity without markedly affecting normal neuronal transmission.

The specific dosing regimen for Lacosamide Ucb is determined by the prescribing clinician based on the patient’s age, weight, renal and hepatic function, and the overall seizure management plan. Healthcare professionals tailor the dose to achieve optimal seizure control while monitoring safety.

The safety of lacosamide in pregnancy and lactation has not been fully established. It should be used only if the potential therapeutic benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To request Lacosamide Ucb, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and import documentation.

Lacosamide belongs to the sodium channel blocker class but uniquely enhances slow inactivation, whereas many older agents (e.g., carbamazepine, phenytoin) affect fast inactivation. This distinct mechanism can offer additional seizure control for patients who have not responded adequately to other sodium‑blocking antiepileptics.

Lacosamide Ucb should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Before administration, allow the product to reach room temperature if required by the clinical protocol, and inspect for particulate matter or discoloration.

Lacosamide Ucb is given by intravenous infusion. The rate and duration of infusion are determined by the treating physician, typically administered over several minutes to an hour, depending on the clinical setting and patient tolerance.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, respiratory depression (especially when combined with other CNS depressants), and emergence of suicidal thoughts. Prompt medical evaluation is essential if any of these occur.

Lacosamide Ucb is contraindicated in patients with known hypersensitivity to lacosamide or any component of the formulation. Caution is advised for individuals with significant cardiac conduction disorders, severe hepatic impairment, or those taking interacting medications that could increase the risk of serious side effects.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lacosamide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT